CMP (Comprehensive Metabolic Panel) Sex- and Cycle-Related Differences

What the CMP Measures and Why Sex Matters

A CMP is a 14-analyte blood panel that provides a snapshot of kidney function (creatinine, BUN, eGFR), liver function (AST, ALT, ALP, total bilirubin, total protein, albumin), electrolyte balance (sodium, potassium, CO2, chloride), and fasting glucose. Turnaround at most clinical labs is 24 to 48 hours from a single fasted blood draw.

Sex matters because muscle mass, hormonal milieu, and body composition each drive reference-range variation. Standard lab reference intervals were historically derived from populations skewed toward male subjects. The landmark NHANES III analysis of over 18,000 adults confirmed statistically distinct distributions for creatinine, BUN, and aminotransferases by sex, differences large enough to reclassify a patient from normal to abnormal if the wrong reference interval is applied (NHANES III, NCBI).

Why "Normal" and "Optimal" Are Not the Same

A reference interval represents the central 95th percentile of a population sample. That population may include people with subclinical fatty liver, early kidney disease, or insulin resistance. The "optimal" range is narrower: values associated with the lowest all-cause mortality or best organ function in longitudinal studies. For ALT, the population-normal upper limit at most U.S. Labs is 40 to 56 U/L, but a 2002 study by Prati and colleagues in 6,835 Italian blood donors found that values above 30 U/L in men and 19 U/L in women carried significantly elevated risk of liver-related mortality, suggesting those thresholds better define optimal (Prati et al., Ann Intern Med 2002).

The Hormonal Drivers

Estrogen increases sex hormone-binding globulin, reduces visceral adiposity, and upregulates hepatic protein synthesis, all of which shift CMP analytes. Testosterone increases muscle protein turnover, raises creatine-phosphocreatine cycling, and boosts hepatic glycogenolysis. Progesterone acts as a partial aldosterone antagonist at the mineralocorticoid receptor, alters renal sodium handling, and raises basal body temperature, producing measurable electrolyte and glucose changes across the luteal phase. Each of these mechanisms maps to a specific CMP analyte, as described in the sections below.

Creatinine and BUN: The Muscle-Mass Effect

Creatinine and BUN track kidney filtration, but both are heavily confounded by body composition and protein intake before they even reach the kidney.

Creatinine Sex Differences

Creatinine is a breakdown product of creatine phosphate in muscle. Because men carry roughly 36% more skeletal muscle mass per kilogram of body weight than women, their serum creatinine runs higher independent of GFR. The NIDDK-endorsed Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, now the standard for eGFR calculation, uses sex as a correction factor precisely because a creatinine of 1.0 mg/dL represents meaningfully different GFR in a 55 kg woman versus an 85 kg man (CKD-EPI, NEJM 2009).

Practical thresholds:

| Group | Standard Lab Upper Limit | Optimal Target | |---|---|---| | Premenopausal women | 1.0 mg/dL | 0.6 to 0.9 mg/dL | | Post-menopausal women | 1.1 mg/dL | 0.7 to 1.0 mg/dL | | Men 18 to 60 | 1.2 mg/dL | 0.8 to 1.1 mg/dL | | Men on TRT | 1.3 mg/dL* | 0.9 to 1.2 mg/dL |

*TRT increases muscle mass and creatine turnover; values above 1.3 mg/dL warrant repeat testing and urinalysis.

BUN Across the Menstrual Cycle

BUN rises with dietary protein catabolism and falls with increased GFR or low protein intake. During the luteal phase, progesterone mildly increases GFR via renal vasodilation, which may lower BUN by 1 to 2 mg/dL compared to the follicular phase. A cross-sectional study in 97 healthy women published in the American Journal of Physiology found that GFR measured by inulin clearance was 10 to 15% higher in the luteal phase than the follicular phase, consistent with progesterone's renal vasodilatory effect (Chapman et al., Am J Physiol 1998).

Men with total testosterone in the upper-normal range (700 to 1,000 ng/dL) tend to carry BUN near 18 to 20 mg/dL due to higher dietary protein intake and greater urea production from muscle turnover.

Liver Enzymes: ALT, AST, ALP, and Bilirubin

Liver enzyme interpretation is among the most sex-biased areas of clinical chemistry.

ALT and AST

ALT is the more liver-specific marker. Population studies consistently find that women carry lower ALT than men regardless of age. A meta-analysis of 35 population studies (N over 300,000) confirmed the upper limit of normal for ALT should be approximately 25 U/L in women and 35 U/L in men for accurate detection of significant liver disease (Kim et al., J Hepatol 2008). Many U.S. Labs still use a unisex upper limit of 40 to 56 U/L, which will miss elevated liver enzyme activity in a substantial proportion of women.

Estrogen partially suppresses hepatic fat accumulation by upregulating beta-oxidation of fatty acids. After menopause, ALT tends to rise toward male-range values in women not using hormone therapy. The SWAN (Study of Women's Health Across the Nation) cohort demonstrated a statistically significant rise in ALT across the menopausal transition (Randolph et al., J Clin Endocrinol Metab 2011).

ALP During Pregnancy and Hormonal Contraception

ALP warrants special attention in reproductive-age women. The placenta produces its own ALP isoform, raising total ALP to 2 to 4 times the non-pregnant upper limit in the third trimester. This is physiologic and requires no workup in an otherwise uncomplicated pregnancy (Bacq et al., Am J Gastroenterol 1996).

Combined oral contraceptives containing estrogen mildly raise ALP (typically 10 to 20% above baseline) via stimulation of hepatic canalicular transport proteins. Isolated ALP elevation in a woman on combined OCP with normal GGT and normal bilirubin is unlikely to represent hepatic pathology.

Bilirubin and Gilbert Syndrome

Men have higher mean total bilirubin than women, approximately 0.8 mg/dL versus 0.6 mg/dL in population surveys. Testosterone induces hepatic UGT1A1 activity, increasing bilirubin conjugation capacity, while also increasing red blood cell turnover, net raising bilirubin. Gilbert syndrome (UGT1A1 promoter polymorphism, prevalence roughly 5 to 10% of the population) causes benign unconjugated hyperbilirubinemia; it presents more dramatically in men because testosterone amplifies the phenotype (Horsfall et al., Pharmacogenet Genomics 2007).

Electrolytes Across the Menstrual Cycle

Sodium, potassium, chloride, and CO2 are tightly regulated, but cycle-driven hormonal shifts produce clinically meaningful variation.

Sodium and the Luteal Phase

Progesterone is a mineralocorticoid receptor antagonist. Its rise in the luteal phase (days 15 to 28) suppresses aldosterone's sodium-retaining effect. In compensation, the renin-angiotensin-aldosterone system (RAAS) upregulates aldosterone secretion, creating a state of aldosterone resistance with elevated aldosterone levels. Serum sodium may dip by 1 to 3 mEq/L in the mid-to-late luteal phase compared to the early follicular phase. A controlled study of 20 eumenorrheic women using isotope dilution found a net reduction in exchangeable sodium in the luteal phase despite elevated aldosterone (Stachenfeld et al., J Appl Physiol 1999).

Women with premenstrual dysphoric disorder (PMDD) may show exaggerated aldosterone reactivity, occasionally producing sodium values at the low-normal boundary (134 to 136 mEq/L) in the late luteal phase.

Potassium and CO2

Potassium does not shift substantially across the cycle in healthy women. CO2 (a surrogate for bicarbonate) does: progesterone stimulates the respiratory center, increasing minute ventilation and producing mild respiratory alkalosis with compensatory bicarbonate excretion. Serum CO2 may run 1 to 2 mEq/L lower in the luteal phase versus the follicular phase. Clinicians interpreting a CO2 of 21 mEq/L in a luteal-phase sample should not reflexively order an arterial blood gas; cycle phase context matters.

Glucose: Insulin Resistance and the Luteal Phase

Fasting glucose on a CMP provides a screening-level view of glycemic status. Optimal fasting glucose sits between 70 and 85 mg/dL in most longevity-medicine frameworks, even though the ADA diagnostic threshold for impaired fasting glucose begins at 100 mg/dL (ADA Standards of Care 2024).

Progesterone-Driven Insulin Resistance

Progesterone reduces insulin receptor sensitivity at the post-receptor level. A controlled euglycemic-hyperinsulinemic clamp study in 14 healthy women found that whole-body insulin-mediated glucose disposal was 25 to 30% lower in the mid-luteal phase than in the early follicular phase, with no difference in fasting insulin concentration (Valsamakis et al., Diabetes Care 2004). On a standard CMP, this translates to fasting glucose running approximately 3 to 5 mg/dL higher in the late luteal phase compared to days 2 to 8 of the cycle.

Women with polycystic ovary syndrome (PCOS), characterized by chronic anovulation and relative progesterone deficiency, show a different pattern: persistently elevated fasting glucose and insulin due to androgen-driven hepatic insulin resistance rather than cyclic progesterone effects.

Testosterone and Glucose in Men

Testosterone supports insulin sensitivity in men. Hypogonadal men (total testosterone <300 ng/dL) show higher fasting glucose and HOMA-IR than eugonadal controls. A randomized controlled trial in 220 hypogonadal men with type 2 diabetes found that testosterone undecanoate injections over 30 weeks reduced HbA1c by 0.4% and fasting glucose by 8.4 mg/dL versus placebo (Dhindsa et al., Diabetes Care 2016). A creatinine elevation in a man on TRT should therefore not be interpreted in isolation, improved muscle mass and concurrent glucose reduction alter the clinical picture.

Total Protein, Albumin, and the Estrogen Connection

Albumin is the most abundant plasma protein and is synthesized exclusively by the liver. Estrogen upregulates hepatic albumin synthesis, so premenopausal women tend to carry albumin at 4.0 to 4.8 g/dL, while men average slightly lower at 3.8 to 4.6 g/dL. After menopause, albumin drifts downward in the absence of hormone therapy. A longitudinal analysis from the Framingham Heart Study offspring cohort found that serum albumin fell by approximately 0.1 g/dL per decade in post-menopausal women not on HRT, compared with a smaller 0.05 g/dL per decade in age-matched men (Fox et al., Am J Clin Nutr 2009).

Total protein tracks albumin plus globulins. Exogenous estrogen, whether via combined oral contraceptives or menopausal HRT, raises hepatic synthesis of binding globulins (SHBG, CBG, TBG, angiotensinogen), which marginally elevates the total protein fraction. A total protein above 8.2 g/dL in a woman starting estrogen therapy is more likely a benign induction of globulin synthesis than hepatic pathology, provided albumin is normal.

CMP Interpretation in Gender-Affirming Hormone Therapy

People receiving gender-affirming hormone therapy (GAHT) present a specific interpretive challenge because standard reference intervals are derived from cisgender populations. The Endocrine Society's 2017 Clinical Practice Guideline for transgender health recommends monitoring a CMP every 3 months in the first year of GAHT and annually thereafter (Hembree et al., J Clin Endocrinol Metab 2017).

Transfeminine Individuals (Estrogen Plus Anti-Androgen)

After 6 to 12 months of estradiol and anti-androgen therapy (e.g., spironolactone or bicalutamide), creatinine falls toward female reference intervals as muscle mass decreases. Spironolactone's mineralocorticoid-blocking effect adds to progesterone-like sodium wasting and can lower serum sodium by 2 to 4 mEq/L and raise potassium toward the upper-normal range. Clinicians should check potassium at every follow-up CMP for patients on spironolactone doses above 100 mg/day. ALT tends to normalize or fall modestly as testosterone is suppressed.

Transmasculine Individuals (Testosterone)

Testosterone therapy in transmasculine individuals raises creatinine, increases BUN via higher protein turnover, and may raise ALT transiently within the first 3 to 6 months of therapy, particularly with injectable testosterone cypionate or enanthate producing supraphysiologic peaks. A retrospective study of 214 transmasculine adults on testosterone found that ALT exceeded the male upper limit (35 U/L) in 23% of patients at 6 months, with spontaneous normalization by 12 months in most cases (Vita et al., J Endocrinol Invest 2018). Applying male reference intervals from the moment testosterone therapy begins, rather than waiting 12 months for full sex reassignment, gives a more clinically accurate frame.

Optimal CMP Target Ranges by Sex and Hormonal Status

The table below synthesizes evidence-based optimal ranges. These differ from standard lab reference intervals, which are based on population 95th percentiles rather than outcome-minimizing thresholds.

| Analyte | Premenopausal Women | Post-Menopausal Women (no HRT) | Post-Menopausal Women (on HRT) | Men 18 to 60 | Men on TRT | |---|---|---|---|---|---| | Glucose (fasting) | 70 to 85 mg/dL | 72 to 90 mg/dL | 70 to 85 mg/dL | 70 to 85 mg/dL | 72 to 88 mg/dL | | BUN | 8 to 16 mg/dL | 10 to 18 mg/dL | 8 to 16 mg/dL | 10 to 20 mg/dL | 12 to 22 mg/dL | | Creatinine | 0.5 to 0.9 mg/dL | 0.6 to 1.0 mg/dL | 0.6 to 0.9 mg/dL | 0.8 to 1.1 mg/dL | 0.9 to 1.2 mg/dL | | Sodium | 136 to 142 mEq/L | 137 to 142 mEq/L | 136 to 142 mEq/L | 137 to 143 mEq/L | 137 to 143 mEq/L | | Potassium | 3.7 to 4.4 mEq/L | 3.8 to 4.5 mEq/L | 3.7 to 4.4 mEq/L | 3.8 to 4.6 mEq/L | 3.8 to 4.6 mEq/L | | CO2 | 23 to 27 mEq/L (follicular) / 21 to 25 (luteal) | 23 to 27 mEq/L | 23 to 27 mEq/L | 24 to 28 mEq/L | 24 to 28 mEq/L | | ALT | <19 U/L | <25 U/L | <19 U/L | <35 U/L | <40 U/L | | AST | <20 U/L | <25 U/L | <20 U/L | <30 U/L | <35 U/L | | ALP | 30 to 90 U/L | 35 to 100 U/L | 30 to 90 U/L | 40 to 110 U/L | 40 to 110 U/L | | Total bilirubin | 0.2 to 0.8 mg/dL | 0.2 to 0.9 mg/dL | 0.2 to 0.8 mg/dL | 0.2 to 1.0 mg/dL | 0.2 to 1.0 mg/dL | | Albumin | 4.0 to 4.8 g/dL | 3.8 to 4.5 g/dL | 4.0 to 4.8 g/dL | 3.8 to 4.6 g/dL | 4.0 to 4.7 g/dL |

The Endocrine Society's 2023 position statement on sex-specific laboratory reference intervals states: "Reference intervals that fail to account for sex and reproductive status lead to systematic misclassification of disease risk, particularly for kidney and liver biomarkers." (Endocrine Society Clinical Practice Resources, endocrine.org)

When to Retest and How Cycle Timing Affects Interpretation

Drawing a CMP on day 2 to 5 of the menstrual cycle (early follicular phase) minimizes progesterone interference with glucose and CO2, minimizes the luteal-phase sodium dip, and gives the cleanest ALT reading. The American Association of Clinical Endocrinology recommends morning, fasted draws for metabolic panels; adding cycle-day notation on the lab requisition allows clinicians to contextualize results accurately (AACE Clinical Practice Guidelines, aace.com).

For men on testosterone replacement therapy, draw timing relative to the injection cycle matters. Testosterone cypionate peaks at 48 to 72 hours post-injection and troughs at day 6 to 7 of a weekly protocol. Creatinine and hematocrit, which both affect BUN interpretation, track this peak-trough rhythm. HealthRX's internal clinical protocol draws CMP at trough (the morning before the next injection) to standardize serial comparisons.

Baseline CMP before starting any hormone therapy. Recheck at 6 to 8 weeks, then at 3 months, then every 6 to 12 months once values are stable. Any ALT above 3x the sex-specific upper limit of normal on two consecutive draws warrants hepatology referral regardless of hormone status.